Table 3 Demographic and clinical characteristics of the sample excluding the individuals carrying a TREM2 rare variant
CDR = 0 (n = 291) | CDR = 0.5 (n = 587) | CDR = 1 (n = 104) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A-/TN- (n = 122) | A+/TN- (n = 52) | A+/TN+ (n = 45) | A-/TN+ (n = 72) | A-/TN- (n = 118) | A+/TN- (n = 93) | A+/TN+ (n = 282) | A-/TN+ (n = 94) | A-/TN- (n = 2) | A+/TN- (n = 15) | A+/TN+ (n = 80) | A-/TN+ (n = 7) | |
Age, y | 72.5 (5.50) | 73.5 (5.95) | 76.3 (5.46) | 74.6 (6.56) | 69.9 (7.56) | 72.6 (7.74) | 73.3 (7.08) | 73.2 (8.16) | 89.2 (1.63) | 76.3 (6.05) | 74.1 (9.28) | 79.8 (8.02) |
Female, n (%) | 58 (47.5) | 24 (46.2) | 24 (53.3) | 40 (55.6) | 55 (46.6) | 21 (22.6) | 119 (42.2) | 42 (44.7) | 0 (0) | 5 (33.3) | 40 (50.0) | 2 (28.6) |
APOE ε4 carriers, n (%) | 17 (13.9) | 20 (38.5) | 27 (60.0) | 15 (20.8) | 24 (20.3) | 47 (50.5) | 216 (76.6) | 32 (34.0) | 0 (0) | 8 (53.3) | 59 (73.8) | 1 (14.3) |
Education, y | 16.4 (2.79) | 16.0 (2.65) | 16.5 (2.55) | 16.4 (2.57) | 16.0 (2.68) | 16.1 (2.97) | 15.9 (2.90) | 15.9 (2.66) | 17.0 (0) | 16.2 (2.51) | 15.1 (2.80) | 15.0 (2.08) |
CSF biomarkers, pg/ml* | ||||||||||||
T-tau | 185 (32.2) | 167 (40.5) | 332 (79.3) | 322 (71.9) | 183.4 (38.2) | 173 (40.0) | 381 (136) | 338 (111) | 234 (6.08) | 188 (38.8) | 393 (136) | 489 (221) |
P-tau181P | 16.2 (2.88) | 15.4 (4.07) | 33.3 (9.09) | 28.9 (7.43) | 15.8 (3.32) | 15.9 (4.14) | 38.9 (14.7) | 31.6 (13.7) | 19.3 (1.20) | 17.4 (3.53) | 39.2 (15.0) | 43.2 (22.9) |
Aβ1-42 | 1456 (223) | 723 (196) | 717 (168) | 1538 (235) | 1428 (247) | 632 (196) | 634 (168) | 1427 (290) | 1330 (14.9) | 538 (185) | 570 (159) | 1484 (290) |
sTREM2 | 3741 (1690) | 2835 (1524) | 4839 (2240) | 5378 (2147) | 3436 (1754) | 2791 (1292) | 4441 (2211) | 5478 (2370) | 5660 (2008) | 3051 (1128) | 3967 (2000) | 7619 (3539) |